Alison de Bord

Director
Alta Partners
San Francisco, CA

Alison joined Alta Partners as an Associate in 2001 and became a Director of Alta Partners VIII in 2006. Her primary investment focus at Alta is on medical technology and biopharmaceuticals. She serves on the board of directors for Aegerion Pharmaceuticals, Insulet Corporation, SurgRx, and Prolacta Bioscience, and prior investments include Esperion Therapeutics and Kerberos Proximal Solutions. Prior to Alta, she was a Senior Associate in Robertson Stephens? Life Sciences Investment Banking Group with primary responsibilities for the execution of corporate finance transactions including IPOs, follow-on equity and convertible preferred offerings. Previously, she was an Associate in Robertson Stephens? Equity Research Group where she focused on growth medical technology companies. She began her career in the business development group at Geron, a biotechnology company. Alison earned a Master of Business Administration from Columbia Business School and a Bachelor of Arts in History from Colgate University